-
EP4054582
European procedure
Extract from the Register of European Patents
EP About this file: EP4054582
| EP4054582 - THERAPEUTIC COMBINATIONS OF ACALABRUTINIB AND CAPIVASERTIB TO TREAT B-CELL MALIGNANCIES [Right-click to bookmark this link] | Status | The patent has been granted Status updated on 01.08.2025 Database last updated on 31.03.2026 | |
| Former | Grant of patent is intended Status updated on 31.03.2025 | ||
| Former | Request for examination was made Status updated on 01.03.2025 | ||
| Former | Grant of patent is intended Status updated on 01.12.2024 | ||
| Former | Request for examination was made Status updated on 12.08.2022 | ||
| Former | The international publication has been made Status updated on 14.05.2021 | ||
| Former | unknown Status updated on 11.11.2020 | Most recent event Tooltip | 30.01.2026 | Lapse of the patent in a contracting state New state(s): BG, RS | published on 04.03.2026 [2026/10] | Applicant(s) | For all designated states Astrazeneca AB 151 85 Södertälje / SE | [2022/37] | Inventor(s) | 01 /
DRY, Hannah AstraZeneca Pharmaceuticals LP, 1800 Concord Pike P.O. Box 15437 Wilmington, Delaware 19850-5437 / US | 02 /
WILLIS, Brandon AstraZeneca Pharmaceuticals LP, 1800 Concord Pike P.O. Box 15437 Wilmington, Delaware 19850-5437 / US | 03 /
BLOECHER, Andrew AstraZeneca Pharmaceuticals LP, 1800 Concord Pike P.O. Box 15437 Wilmington, Delaware 19850-5437 / US | 04 /
METTETAL, Jerome AstraZeneca Pharmaceuticals LP, 1800 Concord Pike P.O. Box 15437 Wilmington, Delaware 19850-5437 / US | [2022/37] | Representative(s) | AstraZeneca Intellectual Property Eastbrook House Shaftesbury Road Cambridge CB2 8BF / GB | [2025/36] |
| Former [2022/37] | AstraZeneca Intellectual Property Milstein Building Granta Park Cambridge CB21 6GH / GB | Application number, filing date | 20800617.1 | 30.10.2020 | [2022/37] | WO2020EP80493 | Priority number, date | US201962930208P | 04.11.2019 Original published format: US 201962930208 P | [2022/37] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021089419 | Date: | 14.05.2021 | Language: | EN | [2021/19] | Type: | A1 Application with search report | No.: | EP4054582 | Date: | 14.09.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 14.05.2021 takes the place of the publication of the European patent application. | [2022/37] | Type: | B1 Patent specification | No.: | EP4054582 | Date: | 03.09.2025 | Language: | EN | [2025/36] | Search report(s) | International search report - published on: | EP | 14.05.2021 | Classification | IPC: | A61K31/4985, A61K31/519, A61P35/00 | [2022/37] | CPC: |
A61P35/00 (EP,KR);
A61K31/4985 (EP,KR,US);
A61K31/519 (EP,KR,US);
A61K2300/00 (KR)
| C-Set: |
A61K31/4985, A61K2300/00 (EP);
A61K31/519, A61K2300/00 (EP) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/37] | Extension states | BA | 07.06.2022 | ME | 07.06.2022 | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | THERAPEUTISCHE KOMBINATIONEN VON ACALABRUTINIB UND CAPIVASERTIB ZUR BEHANDLUNG VON B-ZELL-MALIGNITÄTEN | [2022/37] | English: | THERAPEUTIC COMBINATIONS OF ACALABRUTINIB AND CAPIVASERTIB TO TREAT B-CELL MALIGNANCIES | [2022/37] | French: | ASSOCIATIONS THÉRAPEUTIQUES D'ACALABRUTINIB ET DE CAPIVASERTIB POUR TRAITER DES MALIGNITÉS DE LYMPHOCYTES B | [2022/37] | Entry into regional phase | 07.06.2022 | National basic fee paid | 07.06.2022 | Designation fee(s) paid | 07.06.2022 | Examination fee paid | Examination procedure | 07.06.2022 | Examination requested [2022/37] | 07.06.2022 | Date on which the examining division has become responsible | 30.11.2022 | Amendment by applicant (claims and/or description) | 02.12.2024 | Communication of intention to grant the patent | 27.02.2025 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 01.04.2025 | Communication of intention to grant the patent | 24.07.2025 | Fee for grant paid | 24.07.2025 | Fee for publishing/printing paid | 24.07.2025 | Receipt of the translation of the claim(s) | Fees paid | Renewal fee | 31.10.2022 | Renewal fee patent year 03 | 31.10.2023 | Renewal fee patent year 04 | 31.10.2024 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | BG | 03.09.2025 | HR | 03.09.2025 | LV | 03.09.2025 | RS | 03.12.2025 | [2026/10] |
| Former [2026/09] | HR | 03.09.2025 | |
| LV | 03.09.2025 | ||
| Former [2026/08] | HR | 03.09.2025 | Cited in | International search | [Y] US2017071962 (LANNUTTI BRIAN et al.) | [Y] WO2019211721 (ASTRAZENECA AB et al.) | [Y] JINGJING WU ET AL: "Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor", JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 9, no. 1, 9 March 2016 (2016-03-09), XP055359165, DOI: 10.1186/s13045-016-0250-9 DOI: http://dx.doi.org/10.1186/s13045-016-0250-9 | [Y] WANG MICHAEL ET AL: "Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma", BLOOD CANCER JOURNAL (LEUKEMIA), NATURE PUBLISHING GROUP UK, LONDON, vol. 33, no. 11, 26 September 2019 (2019-09-26), pages 2762 - 2766, XP036920853, ISSN: 0887-6924, [retrieved on 20190926], DOI: 10.1038/S41375-019-0575-9 DOI: http://dx.doi.org/10.1038/s41375-019-0575-9 | [Y] TABEA ERDMANN ET AL: "Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL", BLOOD, vol. 130, no. 3, 20 July 2017 (2017-07-20), pages 310 - 322, XP055768137, DOI: 10.1182/blood DOI: http://dx.doi.org/10.1182/blood-2016-12-758599 | [Y] GIRIJA DASMAHAPATRA ET AL: "The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib", BRITISH JOURNAL OF HAEMATOLOGY, vol. 161, no. 1, 30 January 2013 (2013-01-30), pages 43 - 56, XP055180595, ISSN: 0007-1048, DOI: 10.1111/bjh.12206 DOI: http://dx.doi.org/10.1111/bjh.12206 | [XP] YURI KOSINSKY ET AL: "Quantitative Investigation of Pharmacologically Modulated Signaling and Efficacy in ABC DLBCL Using a Systems Pharmacology Model", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 134, no. 1, 13 November 2019 (2019-11-13), pages 5304, XP009525120, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2019-130879 DOI: http://dx.doi.org/10.1182/blood-2019-130879 | by applicant | WO2013010868 | EP2019072991 | WO2009047563 | J. FOUCQUIER: "Analysis of drug combinations: current methodological landscape", PHARMACOL. RES. PERSPECT., vol. 3, no. 3, June 2015 (2015-06-01), XP055462926, DOI: 10.1002/prp2.149 DOI: http://dx.doi.org/10.1002/prp2.149 | C. J. LEHAR: "Chemical combination effects predict connectivity in biological systems", MOL. SYST. BIOL., vol. 3, 2007, pages 80 | KEITH: "Multicomponent therapeutics for networked systems", NAT. REV. DRUG. DISCOV., vol. 4, 2005, pages 71 - 78, XP055020667, DOI: 10.1038/nrd1609 DOI: http://dx.doi.org/10.1038/nrd1609 |